Sunday, September 30, 2012

Childhoold Cancer Survivors Gather for Event at UAMS


A special event at UAMS Sunday honored Childhood Cancer Awareness Month. Arkansas' First Lady Ginger Beebe was in attendance.

Child cancer survivors, along with their families, came out to the school's Cancer Institute for the party.

Also in attendance, some children currently battling cancer and their parents, seeing there is hope.

One said, "It's really reassuring with what's going on. Everybody's putting forth a lot of effort trying to make it all go away. It's very reassuring with what they're doing for us."

Sunday marked the last day of Childhoold Cancer Awareness Month.

Source: http://arkansasmatters.com/fulltext?nxd_id=591452

Alison Pill gizmodo cnet britney spears sprint Sam Bacile thursday night football

Free Touchscreen Metal Stylus Pen for iPad and iPhone

Sorry, Readability was unable to parse this page for content.

Source: http://feedproxy.google.com/~r/SweetFreeStuff/~3/FXEC30ajV0E/

encyclopedia britannica pi white lion mike d antoni resigns holes ncaa brackets 2012 odd

MSNBC: Israel is trying to push US into war with Iran

Sorry, Readability was unable to parse this page for content.

Source: http://feedproxy.google.com/~r/blacklistednews/hKxa/~3/3paL22qMJ28/M.html

grand canyon skywalk tonga pid corned beef hash the walking dead season 2 finale born free walking dead finale

Novo Nordisk halts development of haemophilia drug

COPENHAGEN (Reuters) - Denmark's Novo Nordisk said on Friday it would discontinue development of its haemophilia drug treatment vatreptacog alfa.

The world's biggest insulin producer said in a statement the development would be discontinued after a few patients in a trial had developed anti-drug antibodies to the treatment, one patient with a potentially neutralising effect.

The drug was intended to replace some of the $1.43 billion annual sales of the company's only other haemophilia drug now on the market - NovoSeven - as it comes off patent.

NovoSeven sales peaked last year as the drug started to come off patent, and Novo Nordisk has said its sales would be flat this year.

The group has four haemophilia drug candidates in late stage three development after discontinuing vatreptacog alfa. It expects to file an application with U.S. and European authorities for haemophilia drug Turoctocog in the fourth quarter of this year.

The company's shares were down 0.2 pct at 1455 GMT, roughly in line with the Copenhagen stock exchange's benchmark index.

(Reporting by Mette Fraende. Editing by Jane Merriman)

Source: http://news.yahoo.com/novo-nordisk-says-discontinue-development-haemophilia-drug-141442756--finance.html

chris anderson rondo suspended bay bridge raul ibanez downton abbey season 3 presidents day band of brothers

tajikistan_news: Kyrgyzstan looks to China http://t.co/eWgeIP2Q